CALR and neoplasm: As predicted, β1−/− cells treated with doxorubicin exhibit significantly higher surface CRT and ERp57 levels compared to the parental WT cells or β1−/− cells re-expressing β1-integrins (Figures 6C,D, Supplementary Figure 4C), consistent with the interpretation that reduced integrin expression enhances CRT exposure on the surface of tumor cells treated with ICD-inducers.